Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer
Open accessThe DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
People with advanced cancer are at heightened risk of desire for hastened death (DHD), suicidal ideation (SI), and completed suicide. Loss of Meaning (LoM), a component of demoralization, can be elevated by a cancer diagnosis and predicts DHD and SI in this population. We completed a randomized controlled trial in which psilocybin-assisted psychotherapy (PAP) produced rapid and sustained improvements in depression, demoralization, and hopelessness in people with cancer. Converging epidemiologic and clinical trial findings suggests a potential antisuicidal effect of this treatment. To probe our hypothesis that PAP relieves SI through its beneficial impacts on depression and demoralization (LoM in particular), we performed secondary analyses assessing within- and between-group differences with regard to LoM and an SI composite score. Among participants with elevated SI at baseline, PAP was associated with within-group reductions in SI that were apparent as early as 8 h and persisted for 6.5 months postdosing. PAP also produced large reductions in LoM from baseline that were apparent 2 weeks after treatment and remained significant and robust at the 6.5 month and 3.2 and 4.5 year follow-ups. Exploratory analyses support our hypothesis and suggest that PAP may be an effective antisuicidal intervention following a cancer diagnosis due to its positive impact on hopelessness and demoralization and its effects on meaning-making in particular. These preliminary results implicate psilocybin treatment as a potentially effective alternative to existing antidepressant medications in patients with cancer that are also suicidal, and warrant further investigation in participants with elevated levels of depression and suicidality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“One of these shows a sustained reduction in demoralization, 62 while the other presents the clinical response rates for depression and anxiety. 61”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Only two long-term 4.5-year follow-up studies are available, involving 4 and 14 patients, respectively. 61,62”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [62]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“with only two secondary analyses providing data on 4.5 years of follow-up, 61,62”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [62]
The cited source says what the claim attributes to it.
In the citing paper
“Open-label studies 25,39,57,78-81 and two followup analyses 61,62 supported the overall positive findings of RCTs.”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [62]
The cited source says what the claim attributes to it.
In the citing paper
“Secondary analyses of these data 4.5 years later found that psilocybin therapy was also associated with reductions in suicidal ideation that were apparent post-intervention and persisting as well as with large reductions in loss of meaning persisting up to 4.5 years”
From Psychosocial and Integrative Oncology: Interventions Across the Disease Trajectory. (2023) · cites this paper as Ross et al. 2021
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Encyclopedia of Psychology, Vol. 3. · doi:10.1037/10518-009 · Cited by 19,744
Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation
Beck, A. T., Steer, R. A., & Carbin, M. G. (1988) · Clinical Psychology Review · doi:10.1016/0272-7358(88)90050-5 · Cited by 11,696
World Health Organization classification of tumors
Kleihues, P., & Sobin, L. H. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12<2887::aid-cncr32>3.0.co;2-f · Cited by 2,377
Suicide and suicidal behaviour
Turecki, G., & Brent, D. A. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00234-2 · Cited by 2,338
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Self-citationPsychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Depression, Hopelessness, and Desire for Hastened Death in Terminally Ill Patients With Cancer
Breitbart, W. (2000) · JAMA · doi:10.1001/jama.284.22.2907 · Cited by 1,110
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
Research works printed but not linked: 2
- Robinson, 2015, A systematic review of the demoralization syndrome in individuals with progressive disease and cancer: a decade of research, J. Pain Symptom Manage., 49, 595, 10.1016/j.jpainsymman.2014.07.008 · DOI · Paper page
- Ross, 2021, Psilocybin
Cited by
Towards an understanding of psychedelic-induced neuroplasticity
Calder, A. E., & Hasler, G. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01389-z · Cited by 313
Yao, Y., Guo, D., Lu, T., Liu, F.-L., Huang, S., Diao, M.-Q., Li, S., Zhang, X.-J., Kosten, T. R., Shi, J., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115886 · Cited by 174
Demoralization in suicide: A systematic review
Costanza, A., Chytas, V., Ambrosetti, J., Shah, S., Amerio, A., Aguglia, A., Serafini, G., Piguet, V., Luthy, C., Cedraschi, C., et al. (2022) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2022.110788 · Cited by 142
Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis
Metaxa, A.-M., & Clarke, M. J. (2024) · BMJ · doi:10.1136/bmj-2023-078084 · Cited by 120
Livne, O., Shmulewitz, D., Walsh, C. A., & Hasin, D. S. (2022) · Addiction · doi:10.1111/add.15987 · Cited by 107
Brennan, W., & Belser, A. B. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.866018 · Cited by 90
Ross, S., Agrawal, M., Griffiths, R. R., Grob, C. S., Berger, A. M., & Henningfield, J. E. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109174 · Cited by 81
Self-citationMaia, L. O., Beaussant, Y., & Garcia, A. C. M. (2022) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2022.01.024 · Cited by 60
Antidepressants for the treatment of depression in people with cancer
Vita, G., Compri, B., Matcham, F., Barbui, C., & Ostuzzi, G. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011006.pub4 · Cited by 73
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
“Reductions in suicidal ideation and loss of meaning (82, 97, 98)”
BackgroundFrom relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS)
Zeifman, R. J., Spriggs, M. J., Kettner, H., Lyons, T., Rosas, F. E., Mediano, P. A. M., Erritzøe, D., & Carhart-Harris, R. L. (2025) · Scientific Reports · doi:10.1038/s41598-023-28111-3 · Cited by 69
Self-citationPsilocybin for Trauma-Related Disorders
Khan, A. J., Bradley, E., O’Donovan, A., & Woolley, J. (2022) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2022_366 · Cited by 67
Schipper, S., Nigam, K. B., Schmid, Y., Piechotta, V., Ljuslin, M., Beaussant, Y., Schwarzer, G., & Boehlke, C. S. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015383.pub2 · Cited by 65
Zeifman, R. J., Wagner, A. C., Monson, C. M., & Carhart-Harris, R. L. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.04.105 · Cited by 60
Self-citationPsychosocial and Integrative Oncology: Interventions Across the Disease Trajectory.
Carlson, L. E. (2023) · Annual Review of Psychology · doi:10.1146/annurev-psych-032620-031757 · Cited by 56
Rosa, W. E., Sager, Z. S., Miller, M. E., Bernstein, I., Rinaldi, A. D., Addicott, K., Ljuslin, M., Adrian, C., Back, A. L., Beachy, J., et al. (2022) · Journal of Palliative Medicine · doi:10.1089/jpm.2022.0036 · Cited by 54
Self-citationStrumila, R., Nobile, B., Korsakova, L., Lengvenytė, A., Olié, É., López‐Castromán, J., Guillaume, S., & Courtet, P. (2021) · Pharmaceuticals · doi:10.3390/ph14121213 · Cited by 48
Distinguishing and treating demoralization syndrome in cancer: A review
Fava, M., Sorg, E. M., Jacobs, J. M., Leadbetter, R. A., & Guidi, J. (2023) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2023.10.004 · Cited by 45
Clinical utility of demoralization: A systematic review of the literature
Woźniewicz, A., & Cosci, F. (2023) · Clinical Psychology Review · doi:10.1016/j.cpr.2022.102227 · Cited by 44
Recent Progress in Mind–Body Therapies in Cancer Care
Deleemans, J. M., Mather, H., Spiropoulos, A., Toivonen, K., Baydoun, M., & Carlson, L. E. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01373-w · Cited by 42
Clinical specificity profile for novel rapid acting antidepressant drugs
Scala, M., Fanelli, G., De Ronchi, D., Serretti, A., & Fabbri, C. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000488 · Cited by 41
Pagni, B. A., Petridis, P. D., Podrebarac, S. K., Grinband, J., Claus, E. D., & Bogenschutz, M. P. (2024) · Scientific Reports · doi:10.1038/s41598-024-52967-8 · Cited by 40
The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns
Johnston, C. B., Mangini, M., Grob, C. S., & Anderson, B. T. (2022) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2022.08.007 · Cited by 40
Psilocybin in Palliative Care: An Update
Whinkin, E., Opalka, M., Watters, C., Jaffe, A., & Aggarwal, S. K. (2023) · Current Geriatrics Reports · doi:10.1007/s13670-023-00383-7 · Cited by 39
Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review
Chisamore, N., Johnson, D. E., Chen, M. J. Q., Offman, H., Chen-Li, D. C. J., Kaczmarek, E. S., Doyle, Z., McIntyre, R. S., & Rosenblat, J. D. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.05.051 · Cited by 34
Psychedelic experiences and long-term spiritual growth: a systematic review
Schutt, W. A., Exline, J. J., Pait, K. C., & Wilt, J. A. (2024) · Current Psychology · doi:10.1007/s12144-024-06272-2 · Cited by 32
Teacher plants — Indigenous Peruvian-Amazonian dietary practices as a method for using psychoactives
Berlowitz, I., O’Shaughnessy, D. M., Heinrich, M., Wolf, U., Maake, C., & Martin-Söelch, C. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114910 · Cited by 32
Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review
Meshkat, S., Malik, G., Zeifman, R. J., Swainson, J., Balachandra, K., Reichelt, A. C., Zhang, Y., Burback, L., Winkler, O., Greenshaw, A. J., et al. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106163 · Cited by 31
Self-citationPsilocybin for major depressive disorder: a systematic review of randomized controlled studies
Li, L., Mo, Y., Shi, Z.-M., Huang, X., Ning, Y.-P., Wu, H., Yang, X.-H., & Zheng, W. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1416420 · Cited by 30
Bobevski, I., Kissane, D. W., McKenzie, D. P., Murphy, G., Perera, C., Payne, I., Lennon, J., Michael, N. G., Grossman, C., & Franco, M. E. (2022) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2022.10.002 · Cited by 27
Dworkin, R. H., Anderson, B. T., Andrews, N., Edwards, R. R., Grob, C. S., Ross, S., Satterthwaite, T. D., & Strain, E. C. (2022) · Journal of Pain · doi:10.1016/j.jpain.2022.05.003 · Cited by 27
Self-citationBeaussant, Y., Tarbi, E., Nigam, K., Miner, S., Sager, Z., Sanders, J. J., Ljuslin, M., Guérin, B., Thambi, P., Tulsky, J. A., et al. (2024) · Cancer · doi:10.1002/cncr.35024 · Cited by 25
Systematic Review of Interventions for Demoralization in Patients With Cancer
Wang, Y., Sun, H., Ji, Q., Wei, J., & Zhu, P. (2023) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000001615 · Cited by 22
Davis, A. K., Levin, A. W., Nagib, P. B., Armstrong, S. B., & Lancelotta, R. L. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-068884 · Cited by 21
“Moreover, evidence suggests a general association between psychedelic administration and reduced suicidality in the general population and in PAT trials, 16–18 suggesting this approach could be helpful regardless of the aetiology of suicidality.”
BackgroundPatchett-Marble, R., O’Sullivan, S., Tadwalkar, S., & Hapke, E. (2022) · Canadian Family Physician · doi:10.46747/cfp.6811823 · Cited by 21
Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Lengvenytė, A., Strumila, R., Olié, É., & Courtet, P. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.02.004 · Cited by 21
Kowalczys, A., Bohdan, M., Wilkowska, A., Pawłowska, I., Pawłowski, L., Janowiak, P., Jassem, E., Lelonek, M., Gruchała, M., & Sobański, P. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.895495 · Cited by 20
Steger, M. F. (2022) · Atlantis highlights in social sciences, education and humanities/Atlantis Highlights in Social Sciences, Education and Humanities · doi:10.2991/978-94-6463-096-1_2 · Cited by 20
Top Ten Tips Palliative Care Clinicians Should Know About Attending to the Existential Experience
Tarbi, E. C., Moore, C. M., Wallace, C. L., Beaussant, Y., Broden, E. G., Chammas, D., Galchutt, P. K., Gilchrist, D., Hayden, A., Morgan, B. E., et al. (2024) · Journal of Palliative Medicine · doi:10.1089/jpm.2024.0070 · Cited by 20
Lehto, R. H., Miller, M., & Sender, J. (2022) · Journal of Holistic Nursing · doi:10.1177/08980101211039086 · Cited by 17
Kelly, D. F., Heinzerling, K. G., Sharma, A., Gowrinathan, S., Sergi, K., & Mallari, R. J. (2022) · Neurosurgery · doi:10.1227/neu.0000000000002275 · Cited by 17
The Emergence of Psilocybin in Psychiatry and Neuroscience
Omidian, H., & Omidian, A. (2025) · Pharmaceuticals · doi:10.3390/ph18040555 · Cited by 16
A transdiagnostic meta-analysis of acute augmentations to psychological therapy
Nord, C. L., Longley, B. F., Dercon, Q., Phillips, V., Funk, J., Gormley, S., Knight, R., Smith, A., & Dalgleish, T. (2023) · Nature Mental Health · doi:10.1038/s44220-023-00048-6 · Cited by 16
Bader, H., Farraj, H., Maghnam, J., & Omar, Y. A. (2024) · World Journal of Clinical Oncology · doi:10.5306/wjco.v15.i7.908 · Cited by 14
Schuman, H. D. M., Savard, C., Mina, R., Barkova, S., Conradi, H. S. W., Deleemans, J. M., & Carlson, L. E. (2025) · Current Oncology · doi:10.3390/curroncol32070380 · Cited by 14
IsHak, W. W., García, P., Pearl, R., Dang, J., William, C., Totlani, J., & Danovitch, I. (2023) · PubMed Central · Cited by 14
The Promise of Psychedelic Science
Olson, D. E. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00071 · Cited by 14
Scala, M., Fabbri, C., Fusar-Poli, P., Di Lorenzo, G., Ferrara, M., Amerio, A., Fusar-Poli, L., Pichiecchio, A., Asteggiano, C., Menchetti, M., et al. (2024) · CNS Spectrums · doi:10.1017/s1092852924002268 · Cited by 13
Psilocybin and Hallucinogenic Mushrooms
Fradet, M., Kelly, C. M., Donnelly, A. J., & Suppes, T. M. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009585330.004 · Cited by 13
Evaluating the potential for psilocybin as a treatment for post-traumatic stress disorder
Miller, C., & Zoladz, P. R. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.124.002237 · Cited by 13
Predictors of therapeutic response to psychedelic-assisted therapy: A systematic review
Viljoen, G., Walter, H., Bendau, A., Koslowski, M., & Betzler, F. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251389581 · Cited by 12
Roseby, W., Kettner, H., Roseman, L., Spriggs, M. J., Lyons, T., Peill, J., Giribaldi, B., Erritzøe, D., Nutt, D. J., & Carhart-Harris, R. L. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1580663 · Cited by 11
A suicide attempt following psilocybin ingestion in a patient with no prior psychiatric history
Kramer, E. N., Reddy, K., & Shapiro, B. B. (2023) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2023.100118 · Cited by 11
Differential impact of resilience on demoralization and depression in Parkinson disease
de Figueiredo, J. M., Zhu, B., Patel, A., Kohn, R., Koo, B. B., & Louis, E. D. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1207019 · Cited by 11
Wong, S., Meckling, G., Fabiano, N., Lee, S., Jones, B. D. M., Shorr, R., Dargél, A., Davis, A. K., Fiedorowicz, J. G., Solmi, M., et al. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251372449 · Cited by 10
Belitzky, E., Carvalho, L. V. R., Taylor, M. V., Naranjo-Ortiz, C., Baum, L. V. M., Fiellin, D. A., & Lustberg, M. B. (2025) · Cancer Medicine · doi:10.1002/cam4.70586 · Cited by 9
Garcia, A. C. M., Maia, L. O., & Reed, P. G. (2024) · Journal of Holistic Nursing · doi:10.1177/08980101241257836 · Cited by 9
Psychedelics and Suicide-Related Outcomes: A Systematic Review
Meshkat, S., Malik, T., Zeifman, R. J., Swainson, J., Zhang, Y., Burback, L., Winkler, O., Greenshaw, A. J., Reichelt, A. C., Vermetten, E. H. G. J. M., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051416 · Cited by 9
Self-citationEMBARK Psychedelic Therapy for Depression: A New Approach for the Whole Person
Brennan, B., & Belser, A. (2024) · doi:10.1093/9780197762622.001.0001 · Cited by 8
Ethical considerations for psychedelic-assisted therapy in military clinical settings
Hoener, S., Wolfgang, A. S., Nissan, D. A., & Howe, E. G. (2023) · Journal of Medical Ethics · doi:10.1136/jme-2023-108943 · Cited by 8
The History, Legalization and Potentials of Psilocybin-Assisted Psychotherapy
Heilman, J. (2023) · Journal of Scientific Exploration · doi:10.31275/20222633 · Cited by 7
Gramling, R. E., Bennett, E., Curtis, K., Richards, W. A., Rizzo, D. M., Arnoldy, F. L., Hegg, L. P., Porter, J., Honstein, H., Pratt, S., et al. (2023) · Journal of Palliative Medicine · doi:10.1089/jpm.2023.0189 · Cited by 7
The therapeutic potential of psychedelic substances in Hospice and Palliative Care
Garcia, A. C. M., & Maia, L. O. (2022) · Progress in Palliative Care · doi:10.1080/09699260.2022.2001140 · Cited by 7
Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury
Plummer, Z., Allen, J., Brand, J., Mayo, L. M., Shultz, S. R., & Christie, B. R. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111448 · Cited by 6
Zhang, X., Zhang, D., Liu, Y., Tian, Y., Yu, F., Cao, Y., & Su, Y. (2024) · Psychology Health & Medicine · doi:10.1080/13548506.2024.2356026 · Cited by 6
Masse-Grenier, M., Chang, S.-L., Bélanger, A., Stephan, J.-F., Hébert, J., Deschamps, P., Plourde, L., Provost, F., Farzin, H., Fallu, J., et al. (2024) · Palliative & Supportive Care · doi:10.1017/s1478951524001494 · Cited by 6
Soto-Angona, Ó., Andión, Ó., Sabucedo, P., Neimeyer, R. A., Haro, J. M., Javkin, J., Farré, M., & González, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-13251-5 · Cited by 5
Allen, J., Sun, M., Baker, T. L., Dames, S., Kryskow, P., Christie, B. R., McDonald, S. J., & Shultz, S. R. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03329-x · Cited by 5
Dwyer, J. L., Johnston, R. B., O’Callaghan, C. C., & Ross, M. (2025) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2025.12.002 · Cited by 5
Pharmacological Strategies for Suicide Prevention Based on the Social Pain Model: A Scoping Review
Rajkumar, R. P. (2022) · Psych · doi:10.3390/psych4030038 · Cited by 5
Bienemann, B., Barbosa, A. R., da Cruz, L. V. M., Multedo, M., & Mograbi, D. C. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2226414 · Cited by 5
Evaluating the value and risks of psychedelics for psychiatric medicine: a clinical perspective
Marazziti, D., Weiss, F., Gurrieri, R., Russomanno, G., Gambini, M., Magnesa, A., Coccoglioniti, A., & Perugi, G. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2445016 · Cited by 5
Modeling of demoralization in breast cancer
de Figueiredo, J. M., Kohn, R., Chung, J. Y., & Gostoli, S. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1554128 · Cited by 5
The Efficacy of Psilocybin in the Treatment of Depression and Anxiety: A Meta-Analysis
Hodge, A. T., Sukpraprut‐Braaten, S., & Strayhan, R. C. (2022) · Current Psychiatry Research and Reviews · doi:10.2174/2666082218666220513142002 · Cited by 5
Meaning and Psychedelics in Palliative Care: A Narrative Review
Alexander, W. B., Hansen, E., Anderson, B. T., Zarrabi, A. J., Rogers, A. H., Loewen, G., Ficcaro, Z. R., Alexander, M. H., Schaefer, D., & Case, A. A. (2025) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2025.10.015 · Cited by 4
Moshfeghinia, R., Mostafavi, S., Jazi, K., Ghasemi, A. R., Khosravani-Nezhad, Y., Narayanan, S., Ahmadi, J., & Pasalar, M. (2026) · BMC Psychology · doi:10.1186/s40359-025-03935-y · Cited by 4
Baker, K. M., Ulrich, C. M., & Meghani, S. H. (2023) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/10499091221147700 · Cited by 4
Exploring the Impact of Recreational Drugs on Suicidal Behavior: A Narrative Review
Moret, R. M., Sanz‐Gómez, S., Gascón, S., & Alacreu‐Crespo, A. (2024) · Psychoactives · doi:10.3390/psychoactives3030021 · Cited by 4
Tang, B. L. (2025) · Psychoactives · doi:10.3390/psychoactives4010005 · Cited by 4
Exploring serotonergic psychedelics as a treatment for personality disorders
Carrithers, B. M., Roberts, D. E., Weiss, B., King, J. D., Carhart-Harris, R. L., Gordon, A. R., Pagni, B. A., Moreau, M., Ross, S., & Zeifman, R. J. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110413 · Cited by 4
Self-citationPsychedelic-Assisted Therapy in Palliative Care—Insights from an International Workshop
Schuldt, A., Clark, I. C., Schmid, Y., Ljuslin, M., Boehlke, C. S., Schipper, S., Sands, M. B., & Blum, D. (2025) · Healthcare · doi:10.3390/healthcare13182275 · Cited by 4
Potential use of psilocybin drugs in the treatment of depression
Śladowska, K., Kawalec, P., Brzostek, T., & Pilc, A. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2264180 · Cited by 4
Psilocybin-Assisted Therapy for Brain Cancer Related Existential Distress: A Case-Report
Stephan, J.-F., & Karam, S. (2024) · Journal of Palliative Medicine · doi:10.1089/jpm.2024.0277 · Cited by 3
Beaussant, Y., Sager, Z. S., Brennan, C. W., Kristan, I., Ljuslin, M., Mazzola, E., Macdonald, D., Murphy, M., Nigam, K. B., Rinaldi, A. D., et al. (2025) · BMJ Supportive & Palliative Care · doi:10.1136/spcare-2025-005773 · Cited by 3
Sinnzentrierte Psychotherapie in der psychoonkologischen Versorgung
Vibrans, L., Lehmann‐Laue, A., & Mehnert-Theuerkauf, A. (2023) · PPmP - Psychotherapie · Psychosomatik · Medizinische Psychologie · doi:10.1055/a-1886-2941 · Cited by 3
Kratina, S., Strıke, C., Schwartz, R. D., Nayfeh, A., Jopling, S. A., Lo, C., & Rush, B. R. (2025) · Social Science & Medicine · doi:10.1016/j.socscimed.2025.118536 · Cited by 2
Matos, R. S., Silva, A. C., Rego, L., Fernandes, R., & Gonçalves, S. D. (2025) · Palliative Medicine · doi:10.1177/02692163251383335 · Cited by 2
Carlson, L. E., Richardson, H., Shore, R., Albertyn, C. P., Balneaves, L. G., Bates, A. T., Burnell, M. J., Chochinov, H. M., Clements, D., Deleemans, J. M., et al. (2025) · Current Oncology · doi:10.3390/curroncol33010007 · Cited by 2
Top Ten Tips Palliative Care Clinicians Should Know About Addressing Suicidality
Lehenaff, R., Oltmann, C., Robbins-Welty, G. A., Scheiner, N. S., Carter, K., Moreno, P. I., Robinson, S., Young, R., & Taylor, E. P. (2026) · Journal of Palliative Medicine · doi:10.1177/10966218261462648 · Cited by 2
N -Cyclohexyltryptamine: freebase, bromide and fumarate
Naeem, M., Le, A. N., Bauer, B. E., Chadeayne, A. R., Golen, J. A., & Manke, D. R. (2023) · Acta Crystallographica Section E Crystallographic Communications · doi:10.1107/s2056989023006217 · Cited by 2
Isidoro, G. M., Paiva, E. M. D. C., Terra, F. D. S., & Garcia, A. C. M. (2024) · Progress in Palliative Care · doi:10.1080/09699260.2023.2300544 · Cited by 2
Cognición extendida y símbolos de la velada mazateca con hongos psilocibios
Caynas-Rojas, S., & Mercadillo, R. E. (2024) · Andamios · doi:10.29092/uacm.v21i54.1063 · Cited by 2
Turner, T., & Glue, P. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2024.0008 · Cited by 2
Tarbi, E. C., Miner, S. A., Nigam, K. B., Sager, Z. S., Sanders, J. J., Ljuslin, M., Guérin, B., Roddy, K., Tulsky, J. A., Agrawal, M., et al. (2025) · Psychedelic Medicine · doi:10.1177/28314425251370303 · Cited by 2
Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations
Yonezawa, K., Hirata, M., Takano, H., Kusudo, K., Tomiyama, S., Harada, L., Suzuki, K., Nutt, D. J., Uchida, H., & Tani, H. (2026) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.70042 · Cited by 1
Morel, N. S., Stenbæk, D. S., Lundberg, J., & Beckman, M. (2026) · BMC Medical Education · doi:10.1186/s12909-026-09124-8 · Cited by 1
Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders
Plourde, L., Chang, S.-L., Nguyen, O., Garel, N., Farzin, H., Stephan, J.-F., Fallu, J., & Dorval, M. (2026) · Palliative Medicine · doi:10.1177/02692163261446141 · Cited by 1
Rodríguez, L., Lyons, J., Maloy, A., & O’Brien, A. (2026) · Campbell Systematic Reviews · doi:10.1177/18911803261469847 · Cited by 1
Probing the Future of Psychedelics for Mental Health
Allen, S. E. (2021) · IEEE Pulse · doi:10.1109/mpuls.2021.3094251 · Cited by 1
Garcia, A. C. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-50864-6_24 · Cited by 1
Metadata
- Authors
- Ross, S., Agin-Liebes, G., Lo, S., Zeifman, R. J., Ghazal, L., Benville, J., Franco Corso, S., Bjerre Real, C., Guss, J., Bossis, A., & Mennenga, S. E.
- Affiliations
- NYU Langone Health (US)
- San Francisco General Hospital (US)
- Pacific University Oregon (US)
- Toronto Metropolitan University (CA)
- Columbia University , , , , ,
- Memorial Sloan Kettering Cancer Center , , , ,
- Corresponding author
- Ross, Stephen
- Venue
- ACS Pharmacology & Translational Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-03-18
- Volume
- 4
- Issue
- 2
- Pages
- 553-562
- ISSN
- 2575-9108 (ISSN-L)
- PMC
- PMC8033770
- OpenAlex
- W3138429576
- Cited by
- 139
- References
- 80
- Citations by year
- 2026: 14 · 2025: 33 · 2024: 40 · 2023: 22 · 2022: 24 · 2021: 6
- FWCI
- 15.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- ACS Pharmacology & Translational Science (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Riverstyx Foundation
- Clinical and Translational Science Institute, New York University
- Heffter Research Institute
- National Institute on Drug Abuse (T32DA007294, T32DA007250)
- National Cancer Institute (P30CA008748)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Palliative and Oncologic Care
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Keywords
- psilocybin-assisted therapy, suicidal ideation, meaninglessness, demoralization, advanced cancer, depression, hopelessness, meaning-making, psychedelic therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.